299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05548283 (ClinicalTrials.gov)	February 1, 2023	16/9/2022	Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study	Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)	Cystic Fibrosis;Cystic Fibrosis Pulmonary Exacerbation	Drug: Beta-lactam antibiotic;Drug: Aminoglycoside	Chris Goss	University of Washington;Medical University of South Carolina;Cystic Fibrosis Foundation	Not yet recruiting	6 Years	N/A	All	730	Phase 4	NULL
2	EUCTR2014-002387-32-GB (EUCTR)	05/08/2014	27/06/2014	Trial of Rosuvastatin for the Prevention of Kidney Toxicity caused by Tobramycin in Children with Cystic Fibrosis	Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis - PROteKT	Aminoglycoside-induced nephrotoxicity MedDRA version: 18.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 18.0;Classification code 10069022;Term: Kidney injury molecule-1;System Organ Class: 10022891 - Investigations MedDRA version: 18.0;Level: LLT;Classification code 10067571;Term: Nephrotoxicity;System Organ Class: 100000004857;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Trade Name: Crestor Product Name: Crestor INN or Proposed INN: Rosuvastatin calcium	University of Liverpool	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	United Kingdom